Director, US ELREXFIO – P2P and Field Engagement Strategy Lead
Listed on 2026-10-30
-
Science
Oncology Care
Role Summary Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry‑leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting‑edge science into market‑shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI‑enabled infrastructure and the authority to accelerate medicines from discovery to delivery.
Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise.
Join us to make history — for patients, for their families, for the future. Every 24 seconds, someone in the world is diagnosed with blood cancer. Despite recent advances, there remain significant unmet needs for patients. With over a decade of experience in Hematology‑Oncology at Pfizer, our impact is driven by our science. Our blood cancer medicines span our three core scientific modalities:
Antibody‑drug conjugates (ADCs), IO biologics including bispecific antibodies (BsAbs) and Small Molecules. There are three major blood cancer types, and Pfizer has treatments within each including Lymphoma, Myeloma, and Leukemia. Currently in the US, Pfizer has six hematologic medicines across its broad portfolio, bringing hope and relief to thousands of people suffering from blood cancers globally. Over the last decade, we've made strides in blood cancers, but our work in Hematology is far from finished.
Role Summary Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry‑leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting‑edge science into market‑shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI‑enabled infrastructure and the authority to accelerate medicines from discovery to delivery.
Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise.
Join us to make history — for patients, for their families, for the future. Every 24 seconds, someone in the world is diagnosed with blood cancer. Despite recent advances, there remain significant unmet needs for patients. With over a decade of experience in Hematology‑Oncology at Pfizer, our impact is driven by our science. Our blood cancer medicines span our three core scientific modalities:
Antibody‑drug conjugates (ADCs), IO biologics including bispecific antibodies (BsAbs) and Small Molecules. There are three major blood cancer types, and Pfizer has treatments within each including Lymphoma, Myeloma, and Leukemia. Currently in the US, Pfizer has six hematologic medicines across its broad portfolio, bringing hope and relief to thousands of people suffering from blood cancers globally. Over the last decade, we've made strides in blood cancers, but our work in Hematology is far from finished.
It is an especially exciting time to join US ELREXFIO as we optimize the TCE indication across peer‑to‑peer channels, and prepare for the next indication in a constantly evolving competitive market.
The US ELREXFIO Director, P2P and Field Engagement Strategy Lead will lead the strategy and execution of how ELREXFIO connects with hematologists and oncologists through peer voices, congress presence, and field‑ready content. This role owns peer‑to‑peer…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).